Attributes | Values |
---|
rdf:type
| |
Description
| - The aim of this work was to evaluate the response of dogs with pituitary-dependent hyperadrenocorticism to treatment with mitotane. The relationship between duration of initial phase of therapy and the initial value of urine cortisol/creatinine ratio (UCCR) was studied. All 14 dogs with pituitary-dependent hyperadrenocorticism were treated. Therapeutic protocol of selective adrenocorticolysis was used. The induction dose of mitotane was 25 mg/kg daily. The length of initial phase of therapy was determined individually on the basis of cortisol production changes, which were monitored by immunoreactive cortisol in urine (UCCR) every 2 - 5 days during the initial phase of treatment. High-dose dexamethasone suppression test was used to differentiate between the pituitary-dependent and adrenal-dependent form of the disease, and the UCCR was measured after dexamethasone suppression. The value of the initial UCCR fluctuated between 58 - 586 x 10-6, the median of UCCR was 138 x 10-6. Initial phase of therapy
- The aim of this work was to evaluate the response of dogs with pituitary-dependent hyperadrenocorticism to treatment with mitotane. The relationship between duration of initial phase of therapy and the initial value of urine cortisol/creatinine ratio (UCCR) was studied. All 14 dogs with pituitary-dependent hyperadrenocorticism were treated. Therapeutic protocol of selective adrenocorticolysis was used. The induction dose of mitotane was 25 mg/kg daily. The length of initial phase of therapy was determined individually on the basis of cortisol production changes, which were monitored by immunoreactive cortisol in urine (UCCR) every 2 - 5 days during the initial phase of treatment. High-dose dexamethasone suppression test was used to differentiate between the pituitary-dependent and adrenal-dependent form of the disease, and the UCCR was measured after dexamethasone suppression. The value of the initial UCCR fluctuated between 58 - 586 x 10-6, the median of UCCR was 138 x 10-6. Initial phase of therapy (en)
- Hlavním cílem práce bylo hodnocení odpovídavosti psů s centrálním hyperadrenokorticizmem na léčbu mitotanem. Byl sledován vztah mezi délkou úvodní fáze terapie a hodnotou iniciálního poměru kortizol/kreatinin (C/C) v moči. K léčbě bylo přistoupeno celkem u 14 psů s centrálním hyperadrenokorticizmem. Byl zvolen terapeutický protokol parciální destrukce kůry nadledvin. Mitotan byl v průběhu úvodní fáze léčby podáván v dávce 25 mg/kg ž.hm./d. Délka iniciální fáze terapie byla určována u každého pacienta individuálně a to na základě změn v produkci kortizolu, které byly monitorovány stanovováním imunoreaktivního kortizolu v moči (poměru C/C) každých 2 - 5 dní úvodní fáze léčby. K rozlišení centrální a periferní formy onemocnění byl užit supresní test s vysokou dávkou dexametazonu, byl stanovován poměr C/C po supresi dexametazonem. Výše iniciálního poměru C/C se v souboru pacientů pohybovala v rozmezí 58 - 586 x 10-6, medián poměru byl 138 x 10-6. Celková délka úvodní fáze léčby se pohybovala v rozmezí 10 (cs)
|
Title
| - Hodnocení odpovídavosti psů s centrálním hyperadrenokorticizmem na léčbu mitotanem, sledování úvodní fáze terapie ve vztahu k iniciální hodnotě poměru kortizol/kreatinin v moči (cs)
- Evaluation of pituitary-dependent hyperadrenocorticism response to mitotane treatment in dogs, the length of initial phase of treatment in relation to the initial value of urine cortisol/creatinine ratio
- Evaluation of pituitary-dependent hyperadrenocorticism response to mitotane treatment in dogs, the length of initial phase of treatment in relation to the initial value of urine cortisol/creatinine ratio (en)
|
skos:prefLabel
| - Hodnocení odpovídavosti psů s centrálním hyperadrenokorticizmem na léčbu mitotanem, sledování úvodní fáze terapie ve vztahu k iniciální hodnotě poměru kortizol/kreatinin v moči (cs)
- Evaluation of pituitary-dependent hyperadrenocorticism response to mitotane treatment in dogs, the length of initial phase of treatment in relation to the initial value of urine cortisol/creatinine ratio
- Evaluation of pituitary-dependent hyperadrenocorticism response to mitotane treatment in dogs, the length of initial phase of treatment in relation to the initial value of urine cortisol/creatinine ratio (en)
|
skos:notation
| - RIV/62157124:16170/01:00000262!RIV06-MSM-16170___
|
http://linked.open.../vavai/riv/strany
| |
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/62157124:16170/01:00000262
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - o; p´-DDD; immunoreactive cortisol in urine; selective adrenocorticolysis; iatrogenic hypoadrenocorticism (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| |
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| |
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Svoboda, Miroslav
- Kolevská, Jana
|
http://linked.open...n/vavai/riv/zamer
| |
issn
| |
number of pages
| |
http://localhost/t...ganizacniJednotka
| |